abstract：:Over the past 30 years there has been an increased use of neoadjuvant (or primary) chemotherapy for treating patients with breast cancer. However, while it is clear that chemotherapy given in the adjuvant setting after surgery does prolong patients' overall and disease-free survival, the evidence that chemotherapy in ...

journal_title：Clinical breast cancer

authors： Heys SD,Hutcheon AW,Sarkar TK,Ogston KN,Miller ID,Payne S,Smith I,Walker LG,Eremin O,Aberdeen Breast Group.

更新日期：2002-10-01 00:00:00

abstract：:Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Su...

journal_title：Clinical breast cancer

authors： Vogel VG,Costantino JP,Wickerham DL,Cronin WM,Wolmark N

更新日期：2002-06-01 00:00:00

abstract：:Preliminary results of a phase II study of gemcitabine plus trastuzumab in previously treated (up to 3 previous regimens) metastatic breast cancer patients are presented. Patients had histologically confirmed metastatic breast cancer, with 2+ or 3+ tumor HER2 expression. Treatment consisted of gemcitabine 1200 mg/m2 o...

journal_title：Clinical breast cancer

authors： O'Shaughnessy J,Vukelja SJ,Marsland T,Kimmel G,Ratnam S,Pippen J

更新日期：2002-05-01 00:00:00

abstract：:The clinical utility of capecitabine as a single agent in metastatic breast cancer has been demonstrated with significant responses seen in women already treated with anthracyclines and taxanes. A phase II study in older women with metastatic breast cancer demonstrated capecitabine to be an effective front-line therap...

journal_title：Clinical breast cancer

authors： Maher JF,Villalona-Calero MA

更新日期：2002-01-01 00:00:00

abstract：:Overexpression of the p185/HER2 protein is seen in 20%-25% of primary breast cancers and is associated with poor prognosis. Recent phase II and III clinical trials demonstrate that trastuzumab is active against breast tumors, both as a single agent and in combination with chemotherapy. In patients with HER2-overexpres...

journal_title：Clinical breast cancer

authors： Pegram MD,O'Callaghan C

更新日期：2001-10-01 00:00:00

abstract：:A pilot chemoprevention study from the Royal Marsden Hospital in the United Kingdom demonstrated that tamoxifen could be administered safely to healthy women. This led to the establishment of multicenter trials, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and Italian National Cancer I...

journal_title：Clinical breast cancer

authors： Ross PJ,Powles TJ

更新日期：2001-04-01 00:00:00

abstract：:The management of metastatic breast cancer is changing as a consequence of extraordinary discoveries in cancer research and the development of more advanced diagnostic technologies. Although traditional chemotherapeutics such as anthracyclines and taxanes still represent the mainstay of treatment for this disease, new...

journal_title：Clinical breast cancer

authors： Cristofanilli M,Hortobagyi GN

更新日期：2001-01-01 00:00:00

abstract：:The sequential use of a doxorubicin combination followed by paclitaxel has been reported to improve disease-free and overall survival in patients with node-positive breast cancer beyond that obtained with doxorubicin/cyclophosphamide combinations. Epirubicin is associated with less cardiotoxicity than doxorubicin and ...

journal_title：Clinical breast cancer

authors： Perez EA

更新日期：2000-09-01 00:00:00

abstract：:Sentinel lymph node dissection (SLND) is a minimally invasive technique to stage axillary lymph nodes in breast cancer. The complications associated with SLND are minimal, especially when compared to routine axillary lymph node dissection (ALND), and it can be performed with an overall identification rate of greater t...

journal_title：Clinical breast cancer

authors： Kelemen PR

更新日期：2000-07-01 00:00:00

abstract：:Hot flashes are the most prominent side effect of tamoxifen, the most frequently prescribed antitumor agent in the world. Little detailed information is available to predict who will develop hot flashes on tamoxifen, to describe the natural history of these hot flashes, and/or to predict who will request therapy for s...

journal_title：Clinical breast cancer

authors： Loprinzi CL,Zahasky KM,Sloan JA,Novotny PJ,Quella SK

更新日期：2000-04-01 00:00:00